|QUANTA DIALYSIS TECHNOLOGIES||CEO||United Kingdom|
| Connected devices redesign healthcare: How are MedTech companies adapting to this new environment? |
John is CEO of Quanta Dialysis Technologies, where he was both a founding board member and an original investor through NBGI Ventures. He had the belief and vision that the initial technology concept of a novel fluid management system could be transformed into a disruptive medical product addressing the unmet needs of the $82 billion global dialysis market by using innovation to empower patients and deliver better outcomes.
John’s career spans more than twenty years, with extensive international experience in building and growing successful healthcare companies as an executive manager, board member, private equity investor and corporate financier. He is currently an Advisory Board member of Digital Health Forum and is a regular speaker and panellist at global medtech and investment conferences. Prior to his role as CEO of Quanta, John was Investment Director at NBGI Ventures, where he was closely involved with a range of innovative medical technology companies in Europe and the US, both as a board member and an investor. John has also held senior positions at Nitec Pharma AG (now Horizon Pharma plc), Atlas Venture and Nomura international and previously served as a member of the i4i selection panel at the NHS National Institute for Health Research. John has also served on the Board of Directors at Cellnovo Ltd, Symetis SA, BoneSupport AB and Advanced Cardiac Therapeutics Inc. He holds a BA in Political Science from The University of Chicago.